S&P 500 index data: S&P 500 Copyright ©
All data supplied by Morningstar Real-Time Data. U.S. intraday real-time exchange quotes are sourced from BATS when available. End-of-day quotes for Nasdaq, NYSE, and Amex securities will appear 15 minutes after close. Graph times are Eastern Standard. © Copyright Morningstar, Inc .
|Enanta Announces AbbVie Submits New Drug Application to the Japanese Ministry of Health, Labour and Welfare for its Investigational, All-Oral, Treatment for Chronic Hepatitis C (2015/2/12)|
|All HCV Patients Treated with a Single SC Administration of 4 mg/kg of RG-101 Responded with Mean Viral Load Reduction of 4.8 log10 at Day 29 and 9/14 Patients are Below the Limit of Quantification at Day 57 (2015/2/9)|
|AbbVie Submits New Drug Application in Japan for its Investigational, All-Oral, Treatment for Chronic Hepatitis C (2015/2/11)|
|The India Fund, Inc. Announces Performance Data And Portfolio Composition (2015/1/5)|
|The India Fund, Inc. Announces Dividend (2014/12/19)|
|The India Fund, Inc. Announces Payment Of Distribution (2015/1/12)|
|The India Fund, Inc. Announces Performance Data And Portfolio Composition (2015/2/2)|
|Enanta Announces 95 percent SVR12 rate in AbbVie’s Phase 3 Study of All-Oral Treatment for Hepatitis C Virus in Japanese Patients (2015/2/2)|
|MN-166 (ibudilast) Progressive MS Abstract Accepted for Presentation at the American Academy of Neurology (AAN) 67th Annual Meeting in Washington, DC (2015/2/1)|
|AbbVie Announces Top-line Results from Phase 3 Study of All-Oral Treatment for Hepatitis C in Japan (2015/1/30)|
Click above to view more mutual fund data and stats for ifn - Infigen Energy.